A “black box” warning on a health product sounds pretty scary – maybe even more so when it’s suddenly being taken off the packaging. Americans were reminded of this type of public health messaging on ...
A series of recent FDA safety actions, drug recalls, label updates and court rulings across pharmacy carry operational implications for pharmacy leaders. The cases span product categories — from a ...
WASHINGTON (AP) — Hormone-based drugs used to treat hot flashes and other menopause symptoms will no longer carry a bold warning label about stroke, heart attack, dementia and other serious risks, the ...
The U.S. Food and Drug Administration is reviewing whether to change the warning label on hormone replacement therapy drugs used to treat menopause symptoms, a move many experts say is long overdue.
The FDA has added new warnings to GLP-1 medications such as Ozempic, Wegovy, and Mounjaro about pulmonary aspiration risk ...
Regulatory Focus' ongoing series of Regulatory Explainers take complicated regulatory topics and make them simple enough for anyone to understand. In our latest Regulatory Explainer, we ...
WASHINGTON — Hormone-based drugs used to treat hot flashes and other menopause symptoms will no longer carry a bold warning label about stroke, heart attack, dementia and other serious risks, the Food ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results